{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:24:08Z","timestamp":1787217848034,"version":"build-2736575974"},"reference-count":30,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Patients with stage IIB\u2013IIIB cutaneous melanoma remain at substantial risk of recurrence despite complete surgical resection. Accurate risk stratification is essential to optimize patient selection for adjuvant therapy and surveillance strategies. We aimed to evaluate the clinicopathological and molecular factors associated with recurrence in a real-world cohort of high-risk melanoma patients. Methods: We retrospectively analyzed 97 patients with stage IIB\u2013IIIB cutaneous melanoma treated at a single tertiary referral center. Clinicopathological characteristics, molecular features, treatment-related variables, and sentinel lymph node (SLN) pathological characteristics were evaluated. Recurrence-free survival (RFS) was estimated using the Kaplan\u2013Meier method. Independent prognostic factors were identified using multivariable Cox proportional hazards regression. Results: After a median follow-up of 88 months, 31 patients (32.0%) developed recurrence. Stage IIC showed the highest recurrence rate in the cohort (52.4%), compared with 25% in stage IIIA and 31.4% in stage IIIB. Consistently, in the multivariable analysis, compared with stage IIB, only stage IIC remained independently associated with worse recurrence-free survival (hazard ratio [HR] = 3.57, 95% confidence interval [CI]: 1.08\u201311.82; p = 0.037), whereas neither stage IIIA nor stage IIIB differed significantly from stage IIB. Female sex was independently associated with a lower risk of recurrence (HR 0.33, 95% CI 0.14\u20130.79; p = 0.012). Although BRAF V600E-mutated tumors showed higher recurrence rates and shorter recurrence-free survival in univariable analyses, BRAF V600E status was not independently associated with recurrence in the multivariable model (p = 0.250). Higher lymphoid infiltration density was associated with improved RFS in univariable analysis, although this finding was limited by substantial missing data and non-standardized pathological assessment. Conclusions: In this exploratory retrospective analysis, female sex and stage IIC were independently associated with RFS. These findings should be interpreted cautiously given the small sample size, limited number of recurrence events, and incomplete availability of some clinicopathological and molecular variables. The prognostic associations observed for BRAF V600E status and lymphoid infiltration, as well as the analyses according to adjuvant treatment, should be considered exploratory and hypothesis-generating. The unfavorable outcomes observed in stage IIC disease support growing evidence that this subgroup represents a biologically aggressive form of melanoma despite the absence of regional nodal involvement. Our findings do not challenge the validity of the AJCC staging system but suggest that clinically relevant heterogeneity may exist within established AJCC stage groups.<\/jats:p>","DOI":"10.3390\/cancers18162694","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:10:20Z","timestamp":1787213420000},"page":"2694","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological Predictors of Recurrence in Resected Stage IIB-IIIB Melanoma: The Prognostic Impact of Stage IIC in a Real-World Cohort"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2573-8039","authenticated-orcid":false,"given":"Ic\u00edar","family":"De La Fuente Dom\u00ednguez","sequence":"first","affiliation":[{"name":"University of C\u00f3rdoba, Maimonides Biomedical Research Institute of C\u00f3rdoba (IMIBIC), Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"},{"name":"Department of Medicine, Faculty of Medicine, University of C\u00f3rdoba, 14071 C\u00f3rdoba, Spain"},{"name":"Medical Oncology Department, Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"S\u00e1nchez Mauri\u00f1o","sequence":"additional","affiliation":[{"name":"University of C\u00f3rdoba, Maimonides Biomedical Research Institute of C\u00f3rdoba (IMIBIC), Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"},{"name":"Department of Medicine, Faculty of Medicine, University of C\u00f3rdoba, 14071 C\u00f3rdoba, Spain"},{"name":"Medical Oncology Department, Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"P\u00e9rez Bartivas","sequence":"additional","affiliation":[{"name":"University of C\u00f3rdoba, Maimonides Biomedical Research Institute of C\u00f3rdoba (IMIBIC), Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"},{"name":"Department of Medicine, Faculty of Medicine, University of C\u00f3rdoba, 14071 C\u00f3rdoba, Spain"},{"name":"Medical Oncology Department, Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"S\u00e1nchez-Lopera","sequence":"additional","affiliation":[{"name":"University of C\u00f3rdoba, Maimonides Biomedical Research Institute of C\u00f3rdoba (IMIBIC), Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"},{"name":"Anatomopathological Department, Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"S\u00e1nchez S\u00e1nchez","sequence":"additional","affiliation":[{"name":"University of C\u00f3rdoba, Maimonides Biomedical Research Institute of C\u00f3rdoba (IMIBIC), Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"},{"name":"Anatomopathological Department, Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Aranda Aguilar","sequence":"additional","affiliation":[{"name":"University of C\u00f3rdoba, Maimonides Biomedical Research Institute of C\u00f3rdoba (IMIBIC), Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"},{"name":"Department of Medicine, Faculty of Medicine, University of C\u00f3rdoba, 14071 C\u00f3rdoba, Spain"},{"name":"Medical Oncology Department, Reina Sof\u00eda University Hospital, 14004 C\u00f3rdoba, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"ref_1","unstructured":"Redecan.org (2025, January 21). Las Estimaciones de la Incidencia del C\u00e1ncer en Espa\u00f1a. Available online: https:\/\/redecan.org\/es\/publicaciones\/40\/redecan-publica-las-estimaciones-de-la-incidencia-del-cancer-en-espana-2026."},{"key":"ref_2","unstructured":"Instituto Nacional de Estad\u00edstica (INE) (2025). Defunciones Seg\u00fan la Causa de Muerte, INE. A\u00f1o 2023."},{"key":"ref_3","unstructured":"REDECAN (2008). Supervivencia de C\u00e1ncer en Espa\u00f1a: Estudio Poblacional del Periodo, REDECAN."},{"key":"ref_4","unstructured":"American Cancer Society (2025, January 21). \u00bfQu\u00e9 es el C\u00e1ncer de Piel Tipo Melanoma?. Available online: https:\/\/www.cancer.org\/es\/cancer\/tipos\/cancer-de-piel-tipo-melanoma\/acerca\/que-es-melanoma.html."},{"key":"ref_5","unstructured":"Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer (2025, January 21). C\u00e1ncer de Piel: Melanoma. S\u00edntomas. Available online: https:\/\/www.contraelcancer.es\/es\/todo-sobre-cancer\/tipos-cancer\/cancer-piel\/melanoma\/sintomas."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ad.2017.05.012","article-title":"Los nuevos sistemas de estadificaci\u00f3n del AJCC incorporan novedades en el c\u00e1ncer cut\u00e1neo","volume":"108","year":"2017","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bellenghi, M., Puglisi, R., Pontecorvi, G., De Feo, A., Car\u00e8, A., and Mattia, G. (2020). Sex and gender disparities in melanoma. Cancers, 12.","DOI":"10.3390\/cancers12071819"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/jid.2010.354","article-title":"Gender differences in melanoma survival: Female patients have a decreased risk of metastasis","volume":"131","author":"Joosse","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_9","first-page":"77","article-title":"Actualizaci\u00f3n en el tratamiento quir\u00fargico del melanoma cut\u00e1neo primario y metast\u00e1sico","volume":"84","year":"2016","journal-title":"Cir. Cir."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejso.2016.08.007","article-title":"Sentinel node biopsy in melanoma: Current controversies addressed","volume":"43","author":"Madu","year":"2017","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","article-title":"Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): A multicentre, randomised, phase 3 trial","volume":"17","author":"Leiter","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e14981","DOI":"10.1111\/dth.14981","article-title":"Early time to recurrence predicts worse survival in patients with localized or regionally advanced cutaneous melanoma","volume":"34","author":"Liang","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.2217\/fon-2022-0508","article-title":"Real-world clinical outcomes of patients with stage IIB or IIC cutaneous melanoma treated at US community oncology clinics","volume":"18","author":"Samlowski","year":"2022","journal-title":"Future Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/jnci\/djaa008","article-title":"Melanoma prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual eighth edition","volume":"112","author":"Bajaj","year":"2020","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study","volume":"42","author":"Luke","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: Primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Prka\u010din, I., Brki\u0107, A., Pondeljak, N., Mokos, M., Ga\u0107ina, K., and \u0160itum, M. (2025). Adjuvant immunotherapy in stage IIB\/IIC melanoma: Current evidence and future directions. Biomedicines, 13.","DOI":"10.3390\/biomedicines13081894"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2010.31.6760","article-title":"Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria","volume":"29","author":"Rutkowski","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/SLA.0b013e31818fefe0","article-title":"Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients","volume":"248","author":"Nowecki","year":"2008","journal-title":"Ann. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"9568","DOI":"10.1200\/JCO.2026.44.16_suppl.9568","article-title":"Assessment of recurrence risk in stage IIB\/C melanoma across time: Implications for stratification and surveillance","volume":"44","author":"Farooq","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamadermatol.2023.3256","article-title":"Stage-specific risk of recurrence and death from melanoma in Denmark, 2008\u20132021: A national observational cohort study of 25,720 patients with stage IA to IV melanoma","volume":"159","author":"Helvind","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e32433","DOI":"10.1016\/j.heliyon.2024.e32433","article-title":"Role of tumor-infiltrating lymphocytes in melanoma prognosis and treatment strategies: A systematic review and meta-analysis","volume":"10","author":"Garutti","year":"2024","journal-title":"Heliyon"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1245\/s10434-022-11478-4","article-title":"Prognostic significance of primary tumor-infiltrating lymphocytes in a contemporary melanoma cohort","volume":"29","author":"Straker","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"108421","DOI":"10.1016\/j.celrep.2020.108421","article-title":"Melanoma persister cells are tolerant to BRAF\/MEK inhibitors via ACOX1-mediated fatty acid oxidation","volume":"33","author":"Shen","year":"2020","journal-title":"Cell Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1245\/s10434-025-17194-z","article-title":"Circulating tumor DNA in high-risk stage II\/III cutaneous melanoma: A feasibility study","volume":"32","author":"Rhodin","year":"2025","journal-title":"Ann. Surg. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/1078-0432.CCR-25-3643","article-title":"Longitudinal ctDNA monitoring for postsurgical disease surveillance in patients with stage I to IIIB melanoma","volume":"32","author":"Ansstas","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1200\/JCO.2026.44.16_suppl.9577","article-title":"Longitudinal monitoring for post-surgical molecular residual disease in patients with stage I\u2013IIIB melanoma using a whole-genome sequencing-based ctDNA assay","volume":"44","author":"Khaddour","year":"2026","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2694\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:30:24Z","timestamp":1787214624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":30,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162694"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162694","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}